Who Owns Amyris Company?

Who owns Amyris now?

The company emerged from Chapter 11 in early 2024 and is now a privately held firm controlled by its primary secured creditor after previous common equity was cancelled. The shift marks a move from consumer brands back to an industrial biotech platform focused on B2B ingredient supply.

Control consolidated under the creditor-led ownership following restructuring, with governance centered on a lean board and management tasked with licensing and margin recovery. Recent divestitures trimmed consumer operations to refocus on scalable fermentation technology and ingredient sales.

Explore related analysis: Amyris Porter's Five Forces Analysis

Founders and Early Ownership of Amyris began in 2003 when scientists from UC Berkeley—Jay Keasling, Jack Newman, Neil Renninger, and Kinkead Reiling—formed the company to commercialize metabolic engineering of yeast, with initial ownership split between the founders and the university and a major non-dilutive grant supporting early work.

Founding Team

Jay Keasling provided core intellectual property on yeast metabolic engineering; three cofounders brought complementary lab and translation expertise.

Early Funding

The Bill and Melinda Gates Foundation contributed $42.6 million in non-dilutive funding to advance artemisinin production for anti-malarial drugs.

Seed and Series A

Venture capital from Kleiner Perkins, Khosla Ventures, and TPG Biotech supplemented founder equity during early rounds.

Institutional Influence

John Doerr and Kleiner Perkins pushed strategic emphasis toward large-scale bio-based fuels and chemicals, shaping governance and capital plans.

Founder Vesting

Standard four-year vesting schedules were used to align founders with long-term scaling and commercialization goals.

Equity Dilution

Subsequent capital-intensive scaling rounds diluted founder stakes as ownership shifted toward venture-backed institutional holders ahead of the public offering.

As lab successes moved toward industrial fermentation, control evolved from a researcher-led startup to a venture-backed company where institutional investors and board members drove strategy, including a pivot from pharmaceuticals to biofuels and specialty chemicals; see a concise company timeline in this Brief History of Amyris.

Key Early Ownership Facts

Founders and early investors set the initial corporate structure and strategic direction, with measurable impacts on later ownership and control.

• Founding year: 2003
• Major non-dilutive grant: $42.6 million from the Bill and Melinda Gates Foundation
• Lead VC investors: Kleiner Perkins, Khosla Ventures, TPG Biotech
• Typical founder vesting: 4 years

Complete Amyris Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping Amyris ownership include the 2010 Nasdaq IPO (~$450,000,000 market cap), strategic investment by an energy partner for bio‑jet fuel, multi‑year capital raises and debt reliance, the August 2023 Chapter 11 filing with over $1.1 billion of debt, and the February 2024 restructuring that left the company privately held.

Ownership evolution shows a transition from a broadly held public biotech to a debt‑driven, single‑owner private company; the current ownership structure of Amyris company is dominated by Foris Ventures after the bankruptcy conversion.

Major stakeholder timeline

Key ownership shifts centered on capital needs and debt conversion, culminating in total consolidation by Foris.

• 2010 IPO created diversified institutional ownership
• TotalEnergies once held a double‑digit stake for bio‑jet fuel collaboration
• By early 2023 Foris Ventures and affiliates held > 30% of common stock and most secured debt
• Post‑restructuring (Feb 2024) Foris owns 100% of the private company

For further context on strategic shifts that influenced Amyris investors and corporate structure, see Marketing Strategy of Amyris

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The current board of directors of the company in 2025 is lean and dominated by appointees of Foris Ventures, prioritizing operational efficiency and a pivot to B2B licensing and ingredient manufacturing over consumer brand activities.

Voting power is concentrated; Foris Ventures holds the vast majority of voting rights, enabling swift governance decisions without public shareholder approvals or SEC proxy filings after the company’s 2023–2024 restructuring and emergence as a private entity.

Board and Voting Power — Key Facts

Foris Ventures’ control streamlines governance, replacing the multi-class public share complexity with a simplified private ownership model focused on tech licensing.

• Foris Ventures: majority voting control after bankruptcy-driven recapitalization in 2023–2024
• Board size reduced to accelerate decision-making and operational turnarounds
• Elimination of public activist risk; long-term mandate over quarterly pressure
• Primary focus: monetize proprietary yeast strains via B2B partnerships and ingredient manufacturing

See additional context on corporate strategy and ownership shifts in our detailed analysis: Growth Strategy of Amyris

Amyris Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Since emerging from bankruptcy in February 2024, Amyris’s ownership profile shifted from public shareholders to concentrated private control, driven by a $190,000,000 exit financing from Foris Ventures and a broad divestiture of consumer brands to stabilize the balance sheet.

The company abandoned its vertical integration model (2016–2022) and moved to a streamlined asset-light structure focused on its core fermentation platform and R&D in Emeryville, with Foris Ventures acting as the primary backer and likely long-term owner.

Bankruptcy exit and financing

Foris Ventures provided a $190,000,000 exit facility enabling the Feb 2024 emergence and immediate balance-sheet stabilization.

Consumer brand sales

Biossance sold for $20,000,000; other brands (Pipette, 4U by Tia, Rose Inc.) were liquidated or sold in 2024–2025 to reduce cash burn.

Industry consolidation trend

Synthetic biology peers signal consolidation and emphasis on proven unit economics over speculative growth; private control models are increasingly common.

Ownership outlook

With no announced IPO plans through 2025, Amyris is expected to remain privately controlled by Foris Ventures while aiming to position its fermentation platform for a potential strategic sale once cash flow is stable. See Competitors Landscape of Amyris for comparative context.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE